Wednesday, 22 Jan 2020

PsA/SpA

Date Typesort ascending Title Save
08 Feb 2016 Social Acute sacroiliitis Dx by bone or CT scan. Causes include pyogenic infx, brucellosis, crystal induced, neoplasia https://t.co/toLl8suM0i
07 Nov 2017 Social RT @Janetbirdope: #GAMECHANGER. Ankylosing spondylitis genetics are biased AS parent is more likely to have AS in sons #acr17 @rheumnow #1
29 Sep 2017 Social Higher MASEI (enthesitis) scores in PsA assoc w/ more Jt damage, ankylosis, arthritis mutilans periostitis, axial Dz https://t.co/NKw37wkka5
29 Dec 2017 Social Causes of Dactylitis = PsA, AS, SpA, reactive arthritis, MCTD, PSS, TB, syphilis, JIA, Sarcoid https://t.co/nhotKuYF2n
17 Jun 2019 Social RT @tuna0sashimi: FUTURE 5 secukinumab in PsA placebo arm only 12w. Week 52 pt can increase doses from 150mg to 300mg. 2y data presented. S…
11 Nov 2019 Social RT @EBRheum: RCT Tildrakizumab (IL23i) in Psoriatic Arthritis Beat PLBO for ACR20 (NNT~4), ACR50 (NNT~4), and pt global (NNT~3 for 50% imp…
27 Jul 2015 Social Having cholecystectomy-confirmed gallstones was assoc w/ risk of psoriasis (RR 2·20) & concomitant PsA (RR 4·41) http://t.co/xW9BuiTQHR
04 Jan 2017 Social NICE recommends apremilast for use in psoriatic arthritis w/in UK NHS. Risk of suidical ideation is 0.2% (3/1441) https://t.co/ZFDSo3B81u
07 Nov 2017 Social RT @Lupusdoc: Poster title of the day....! #2556 @RheumNow #ACR17 https://t.co/nDmsAQQS19
17 Feb 2017 Social RT @DrRachelTate: Tofa as an option for AS? No FDA indication but a potential off label option. E. Ruderman MD #rwcs2017 @RWCSmtg @RheumNow…
19 Feb 2018 Social 2018 AAD presentations on upadacitinib (Abbvies JAK1 inhibitor) shows it effective in reducine pruritus, with rapid responses in psoriasis by Week. Also under study for atopic dermatitis and more. https://t.co/6c4yauVPCC
13 Jan 2019 Social QD Video on RheumNow - an HLA-B27+ patient with Iritis, Enthesitis, Diarrhea. https://t.co/LusZttdAyw
12 Nov 2019 Social RT @uptoTate: COAST-X: IXE met ASAS 40 and all secondary endpoints in nr-axSpA vs PBO. https://t.co/V0QNfi33eA #ACR19 @RheumNow plenary#272…
16 Oct 2017 Social Population survey found psoriasis/PsA in 1.4-3.3%; Nearly 1/2 not seeing MD or stopped biologic for safety/no effect https://t.co/JGHWuIUacK
08 Jun 2016 Social Secukinumab data presented at EULAR; Novartis plans H2H trial of Cosentyx & Humira; details to follow https://t.co/zjA8Rgw0cX
28 Mar 2017 Social RT @CBSHealth: FDA approves powerful new drug for eczema -- but it comes with a hefty price tag https://t.co/EOjOgCdoci https://t.co/V49wgh…
14 Jul 2016 Social in 428 SpA pts, BMI (obesity) has no effect on ASDAS. BMI weakly correlates w/ CRP, other PRO's. https://t.co/FcTfEicYpN
14 Oct 2018 Social RheumNow Wk in Review is up! Info on SSc-SSLE overlap, capillaroscopy fingers, Women with SpA, acute gout management and lupus patients in pain in the ED. Watch here https://t.co/wB10SaVXF7 Or checkout the podcasts at iTunes or here https://t.co/5GdSlCyWmW
30 Sep 2019 Social Tofacitinib therapy is being studied (not yet approved) in several dermatologic conditions - psoriasis, alopecia areata/universalis, vitiligo, atopic dermatitis and dermatomyositis. https://t.co/Ez3u95Eh7K
13 Nov 2019 Social RT @uptoTate: Tildrakizumab (TIL), anti–IL-23p19 monoclonal ab, superior to PBO in phase 2b trial results in PsA. https://t.co/i0vIEHD4hx #…